Replimune (REPL) Income from Continuing Operations (2017 - 2026)
Replimune (REPL) posted Income from Continuing Operations of 73168000.0 for Q1 2026, down 3.14% sequentially from 70941000.0 in Q4 2025, and up 1.34% YoY from 72200292.94 in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Replimune has reported Income from Continuing Operations for 10 years, with the latest figure at 73168000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 1.34% year-over-year to 73168000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 395750000.0 (down 60.01% YoY) and the FY2026 annual result came in at 313891000.0, down 26.91% from the prior year.
- Income from Continuing Operations slipped to 73168000.0 in Q1 2026 per REPL's latest filing, from 70941000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 31615000.0 in Q1 2022 and troughed at 128724000.0 in Q2 2025.
- A 5-year average of 62634352.94 and a median of 53772000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations surged 51.52% in 2022, then plunged 139.39% in 2025.
- Over 5 years, Income from Continuing Operations stood at 39690000.0 in 2022, then fell by 28.8% to 51120000.0 in 2023, then declined by 29.77% to 66340000.0 in 2024, then declined by 6.94% to 70941000.0 in 2025, then retreated by 3.14% to 73168000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 73168000.0, 70941000.0, and 122917000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | -68.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -68.87 Mn |
| Mar 31, 2026 | -73.17 Mn |
| Dec 31, 2025 | -70.93 Mn |
| Sep 30, 2025 | -82.08 Mn |
| Jun 30, 2025 | -87.18 Mn |
| Mar 31, 2025 | -74.14 Mn |
| Dec 31, 2024 | -66.37 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -55.05 Mn |
| Dec 31, 2023 | -51.15 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.25 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.86 Mn |
| Dec 31, 2021 | -29.61 Mn |
| Sep 30, 2021 | -29.17 Mn |